Allergan PLC. Stock Price, News & Analysis (NYSE:AGN)

$174.88 0.07 (0.04 %)
(As of 11/17/2017 04:00 PM ET)
Previous Close$174.81
Today's Range$172.85 - $176.24
52-Week Range$169.61 - $256.80
Volume2.82 million shs
Average Volume2.91 million shs
Market Capitalization$57.55 billion
P/E Ratio11.14
Dividend Yield1.62%
Beta1.12

About Allergan PLC. (NYSE:AGN)

Allergan PLC. logoAllergan, Inc. is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets. The Company operates in two segments: specialty pharmaceuticals and medical devices. The specialty pharmaceuticals segment produces products, including ophthalmic products for dry eye, glaucoma, inflammation, infection, allergy and retinal disease; Botox for therapeutic and aesthetic indications; skin care products for acne, psoriasis, eyelash growth and prescription and OTC skin care products, and urologics products. The medical devices segment produces medical devices, including breast implants for augmentation, revision and reconstructive surgery and tissue expanders, and facial aesthetics products.


Industry, Sector and Symbol:
  • Industry: Drugs - Generic
  • Sub-Industry: Pharmaceuticals
  • Sector: Medical
  • Symbol: NYSE:AGN
  • Previous Symbol: NYSE:ACT
  • CUSIP: 01849010
  • Web: www.allergan.com
Debt:
  • Debt-to-Equity Ratio: 0.40%
  • Current Ratio: 1.18%
  • Quick Ratio: 1.08%
Price-To-Earnings:
  • Trailing P/E Ratio: 11.14
  • Forward P/E Ratio: 10.74
  • P/E Growth: 1.09
Sales & Book Value:
  • Annual Sales: $14.5706 billion
  • Price / Sales: 3.99
  • Cash Flow: $33.12 per share
  • Price / Cash: 5.28
  • Book Value: $199.18 per share
  • Price / Book: 0.88
Dividend:
  • Annual Dividend: $2.80
  • Dividend Yield: 1.6%
Profitability:
  • Trailing EPS: ($22.59)
  • Net Income: $14.9734 billion
  • Net Margins: -47.27%
  • Return on Equity: 8.00%
  • Return on Assets: 4.45%
Misc:
  • Employees: 16,700
  • Outstanding Shares: 332,580,000
 
Frequently Asked Questions for Allergan PLC. (NYSE:AGN)

What is Allergan PLC.'s stock symbol?

Allergan PLC. trades on the New York Stock Exchange (NYSE) under the ticker symbol "AGN."

How often does Allergan PLC. pay dividends? What is the dividend yield for Allergan PLC.?

Allergan PLC. declared a quarterly dividend on Friday, October 27th. Stockholders of record on Friday, November 17th will be paid a dividend of $0.70 per share on Friday, December 15th. This represents a $2.80 annualized dividend and a dividend yield of 1.60%. The ex-dividend date of this dividend is Thursday, November 16th. View Allergan PLC.'s Dividend History.

How will Allergan PLC.'s stock buyback program work?

Allergan PLC. declared that its board has initiated a stock buyback plan on Tuesday, September 26th 2017, which permits the company to repurchase $2,000,000,000.00 in outstanding shares, according to EventVestor. This repurchase authorization permits the company to repurchase up to 2.8% of its stock through open market purchases. Stock repurchase plans are often a sign that the company's board believes its shares are undervalued.

How were Allergan PLC.'s earnings last quarter?

Allergan PLC. (NYSE:AGN) posted its quarterly earnings data on Wednesday, November, 1st. The company reported $4.15 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $4.06 by $0.09. The business earned $4.03 billion during the quarter, compared to the consensus estimate of $4.04 billion. Allergan PLC. had a positive return on equity of 8.00% and a negative net margin of 47.27%. The firm's revenue was up 11.4% on a year-over-year basis. During the same period in the prior year, the company earned $3.32 earnings per share. View Allergan PLC.'s Earnings History.

When will Allergan PLC. make its next earnings announcement?

Allergan PLC. is scheduled to release their next quarterly earnings announcement on Tuesday, February, 6th 2018. View Earnings Estimates for Allergan PLC..

What guidance has Allergan PLC. issued on next quarter's earnings?

Allergan PLC. issued an update on its FY17 earnings guidance on Wednesday, November, 1st. The company provided earnings per share (EPS) guidance of $16.15-16.45 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $16.21. The company issued revenue guidance of $15.875-16.025 billion, compared to the consensus revenue estimate of $15.90 billion.

Where is Allergan PLC.'s stock going? Where will Allergan PLC.'s stock price be in 2017?

19 analysts have issued 1 year target prices for Allergan PLC.'s stock. Their predictions range from $191.00 to $280.00. On average, they expect Allergan PLC.'s share price to reach $245.00 in the next twelve months. View Analyst Ratings for Allergan PLC..

What are Wall Street analysts saying about Allergan PLC. stock?

Here are some recent quotes from research analysts about Allergan PLC. stock:

  • 1. According to Zacks Investment Research, "Allergan boasts dominant growth franchises in several areas and is strengthening its product portfolio through strategic acquisitions. Key products like Botox and Linzess and new products such as Viberzi and Vraylar, are supporting sales growth. It also boasts a strong branded pipeline. Biosimilars also represent significant opportunity. However, while we remain optimistic about the company’s growth prospects, it is facing generic competition for legacy brands like Namenda and Asacol HD as well as patent challenges for some of the other products in its branded portfolio, which concerns us. Also, competition for key growth drivers, Restasis and Linzess, is an investor concern. Though Allergan’s shares have declined this year so far, they have performed better than the industry. Estimates have declined slightly ahead of the Q3 earnings release. The company has a mixed record of earnings surprises in recent quarters." (10/23/2017)
  • 2. Cantor Fitzgerald analysts commented, "Allergan announced mixed top-line results from its Phase 2b study of CVC for NASH. The Street was waiting for this, and the delay relative to Street expectations had been one reason the stock has been weak." (9/22/2017)
  • 3. Leerink Swann analysts commented, "AGN modestly beat our 4Q topline forecast (+1.3%) while Non-GAAP EPS beat our forecast by +3.8%. Given the 4Q strength of AGN's aesthetic franchises we're modestly raising our sales and EPS estimates." (2/9/2017)

Who are some of Allergan PLC.'s key competitors?

Who owns Allergan PLC. stock?

Allergan PLC.'s stock is owned by many different of institutional and retail investors. Top institutional investors include Edgewood Management LLC (1.34%), Bank of New York Mellon Corp (1.03%), Baupost Group LLC MA (0.89%), Epoch Investment Partners Inc. (0.54%), Parnassus Investments CA (0.54%) and Legal & General Group Plc (0.52%). Company insiders that own Allergan PLC. stock include Brent L Saunders, Maria Teresa Hilado, Nesli Basgoz and Paul Bisaro. View Institutional Ownership Trends for Allergan PLC..

Who sold Allergan PLC. stock? Who is selling Allergan PLC. stock?

Allergan PLC.'s stock was sold by a variety of institutional investors in the last quarter, including Parnassus Investments CA, Bessemer Group Inc., American Century Companies Inc., Mar Vista Investment Partners LLC, APG Asset Management N.V., Jackson Square Partners LLC, Morningstar Investment Services LLC and Los Angeles Capital Management & Equity Research Inc.. Company insiders that have sold Allergan PLC. company stock in the last year include Nesli Basgoz and Paul Bisaro. View Insider Buying and Selling for Allergan PLC..

Who bought Allergan PLC. stock? Who is buying Allergan PLC. stock?

Allergan PLC.'s stock was purchased by a variety of institutional investors in the last quarter, including Edgewood Management LLC, Baupost Group LLC MA, Asset Management One Co. Ltd., Point72 Asset Management L.P., Russell Investments Group Ltd., Iridian Asset Management LLC CT, Rothschild Asset Management Inc. and Cramer Rosenthal Mcglynn LLC. Company insiders that have bought Allergan PLC. stock in the last two years include Brent L Saunders and Maria Teresa Hilado. View Insider Buying and Selling for Allergan PLC..

How do I buy Allergan PLC. stock?

Shares of Allergan PLC. can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Allergan PLC.'s stock price today?

One share of Allergan PLC. stock can currently be purchased for approximately $174.88.

How big of a company is Allergan PLC.?

Allergan PLC. has a market capitalization of $57.55 billion and generates $14.5706 billion in revenue each year. The company earns $14.9734 billion in net income (profit) each year or ($22.59) on an earnings per share basis. Allergan PLC. employs 16,700 workers across the globe.

How can I contact Allergan PLC.?

Allergan PLC.'s mailing address is CLONSHAUGH BUSINESS AND TECHNOLOGY PARK COOLOCK, DUBLIN L2, D17 E400. The company can be reached via phone at 353-1435-7700 or via email at [email protected]


MarketBeat Community Rating for Allergan PLC. (NYSE AGN)
Community Ranking:  3.5 out of 5 (star star star half star)
Outperform Votes:  907 (Vote Outperform)
Underperform Votes:  402 (Vote Underperform)
Total Votes:  1,309
MarketBeat's community ratings are surveys of what our community members think about Allergan PLC. and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Analysts' Consensus Ratings for Allergan PLC. (NYSE:AGN) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 0 Sell Ratings, 8 Hold Ratings, 11 Buy Ratings, 0 Strong Buy Ratings
Consensus Rating:Buy (Score: 2.58)
Consensus Price Target: $245.00 (40.10% upside)
Consensus Price Target History for Allergan PLC. (NYSE:AGN)
Price Target History for Allergan PLC. (NYSE:AGN)
Analysts' Ratings History for Allergan PLC. (NYSE:AGN)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
11/2/2017Morgan StanleyLower Price TargetEqual Weight$228.00 -> $200.00N/AView Rating Details
11/2/2017Cantor FitzgeraldLower Price TargetNeutral$191.00N/AView Rating Details
11/2/2017Wells Fargo & CompanyReiterated RatingOutperform$258.00 -> $245.00N/AView Rating Details
11/2/2017Royal Bank Of CanadaLower Price TargetOutperform -> Outperform$250.00 -> $221.00N/AView Rating Details
10/22/2017J P Morgan Chase & CoSet Price TargetBuy$275.00N/AView Rating Details
10/20/2017Cowen and CompanySet Price TargetBuy$400.00 -> $280.00N/AView Rating Details
10/19/2017Citigroup Inc.Lower Price TargetBuy$280.00 -> $240.00N/AView Rating Details
10/19/2017MizuhoDowngradeBuy -> Neutral$193.00 -> $193.00N/AView Rating Details
10/18/2017Edward JonesReiterated RatingBuy -> HoldN/AView Rating Details
10/18/2017Sanford C. BernsteinSet Price TargetBuy$296.00 -> $252.00N/AView Rating Details
10/17/2017Deutsche Bank AGSet Price TargetBuy$251.00N/AView Rating Details
10/17/2017Credit Suisse GroupSet Price TargetOutperform$266.00 -> $243.00N/AView Rating Details
10/13/2017Piper Jaffray CompaniesSet Price TargetHold$227.00N/AView Rating Details
10/2/2017Barclays PLCReiterated RatingEqual WeightLowView Rating Details
8/14/2017ArgusReiterated RatingBuy$280.00LowView Rating Details
5/10/2017Goldman Sachs Group, Inc. (The)DowngradeBuy -> Neutral$262.00HighView Rating Details
2/9/2017Leerink SwannBoost Price TargetBuy$280.00N/AView Rating Details
12/23/2016Bank of America CorporationReiterated RatingBuy$280.00N/AView Rating Details
11/21/2016William BlairReiterated RatingMarket PerformN/AView Rating Details
4/18/2016GuggenheimInitiated CoverageNeutralN/AView Rating Details
4/12/2016S&P Equity ResearchReiterated RatingBuyN/AView Rating Details
4/7/2016Raymond James Financial, Inc.Lower Price TargetOutperform$317.00 -> $275.00N/AView Rating Details
4/7/2016Canaccord GenuityReiterated RatingBuyN/AView Rating Details
4/7/2016Susquehanna Bancshares IncDowngradePositive -> Neutral$345.00 -> $275.00N/AView Rating Details
4/5/2016NomuraReiterated RatingBuy$350.00 -> $330.00N/AView Rating Details
(Data available from 11/17/2015 forward)

Earnings

Earnings History for Allergan PLC. (NYSE:AGN)
Earnings by Quarter for Allergan PLC. (NYSE:AGN)
Earnings History by Quarter for Allergan PLC. (NYSE AGN)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/6/2018N/AView Earnings Details
11/1/2017Q3 2017$4.06$4.15$4.04 billion$4.03 billionViewN/AView Earnings Details
8/3/2017Q2 2017$3.95$4.02$3.95 billion$4.01 billionViewListenView Earnings Details
5/9/2017Q1 2017$3.32$3.35$3.53 billion$3.57 billionViewListenView Earnings Details
2/8/2017Q416$3.76$3.90$3.77 billion$3.86 billionViewListenView Earnings Details
11/2/2016Q316$3.57$3.32$3.73 billion$3.62 billionViewListenView Earnings Details
8/8/2016Q216$3.34$3.35$4.10 billion$3.68 billionViewListenView Earnings Details
5/10/2016Q116$3.03$3.04$3.97 billion$3.80 billionViewListenView Earnings Details
2/22/2016Q415$3.36$3.41$4.20 billion$4.20 billionViewListenView Earnings Details
11/4/2015Q315$3.20$3.48$5.71 billion$4.10 billionViewN/AView Earnings Details
8/6/2015Q215$4.41$4.41$5.71 billion$5.76 billionViewN/AView Earnings Details
5/11/2015Q115$3.84$4.30$4.04 billion$4.23 billionViewListenView Earnings Details
2/18/2015Q414$3.67$3.91$3.84 billion$4.01 billionViewN/AView Earnings Details
11/5/2014Q414$1.83$2.17$1.90 billion$1.91 billionViewN/AView Earnings Details
11/5/2014Q314$3.10$3.19$3.63 billion$3.68 billionViewN/AView Earnings Details
8/5/2014Q314$1.76$1.78$1.78 billion$1.79 billionViewListenView Earnings Details
8/5/2014Q214$3.36$3.42$2.55 billion$2.67 billionViewN/AView Earnings Details
7/21/2014Q214$1.44$1.51$1.77 billion$1.83 billionViewN/AView Earnings Details
4/30/2014Q114$1.13$1.18$1.60 billion$1.65 billionViewN/AView Earnings Details
4/30/2014Q114$3.23$3.49$2.59 billion$2.66 billionViewListenView Earnings Details
2/20/2014Q413$3.05$3.17$2.68 billion$2.78 billionViewListenView Earnings Details
2/4/2014Q413$1.34$1.12$1.65 million$1.66 millionViewN/AView Earnings Details
10/29/2013Q313$1.20$1.23$1.53 billion$1.23 billionViewListenView Earnings Details
10/29/2013Q313$2.09$2.09$2.04 billion$2.01 billionViewListenView Earnings Details
7/31/2013Q2 2013$1.20$1.22$1.56 billion$1.60 billionViewN/AView Earnings Details
7/25/2013Q2 2013$2.00$2.01$1.99 billion$1.99 billionViewListenView Earnings Details
5/2/2013Q1 2013$1.86$1.99$1.97 billion$1.90 billionViewListenView Earnings Details
5/1/2013Q1 2013$0.96$0.98$1.44 billion$1.46 billionViewN/AView Earnings Details
2/19/2013Q4 2012$1.53$1.59$1.74 million$1.75 billionViewListenView Earnings Details
2/5/2013Q4 2012$1.20$1.15$1.51 million$1.48 millionViewN/AView Earnings Details
10/30/2012Q312$1.04$1.06$1.43 billion$1.39 billionViewN/AView Earnings Details
8/1/2012$1.06$1.07ViewN/AView Earnings Details
5/2/2012$0.87$0.86ViewN/AView Earnings Details
2/2/2012$1.00$1.00ViewN/AView Earnings Details
10/26/2011$0.90$0.92ViewN/AView Earnings Details
8/3/2011$0.95$0.96ViewN/AView Earnings Details
5/4/2011$0.74$0.77ViewN/AView Earnings Details
2/2/2011$0.89$0.88ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Allergan PLC. (NYSE:AGN)
2017 EPS Consensus Estimate: $16.28
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172$3.33$3.55$3.44
Q2 20172$4.00$4.07$4.04
Q3 20173$4.03$4.16$4.09
Q4 20174$4.61$4.84$4.71
(Data provided by Zacks Investment Research)

Dividends

Current Dividend Information for Allergan PLC. (NYSE:AGN)
Next Dividend:12/15/2017
Annual Dividend:$2.80
Dividend Yield:1.60%
Dividend Growth:0.00% (3 Year Average)
Payout Ratio:-12.39% (Trailing 12 Months of Earnings)
17.20% (Based on This Year's Estimates)
17.31% (Based on Next Year's Estimates)
Frequency:Quarterly Dividend
Dividend Payments by Quarter for Allergan PLC. (NYSE:AGN)

Dividend History by Quarter for Allergan PLC. (NYSE AGN)
AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
10/27/2017quarterly$0.701.58%11/16/201711/17/201712/15/2017
8/2/2017Quarterly$0.701.12%8/16/20178/18/20179/15/2017
5/5/2017quarterly$0.700.01%5/16/20175/18/20176/15/2017
11/2/2016quarterly$0.702/24/20172/28/20173/28/2017
2/4/2015quarterly$0.050.09%2/5/20152/9/20153/20/2015
10/27/2014quarterly$0.0511/20/201412/11/2014
7/28/2014quarterly$0.050.12%8/13/20148/15/20149/5/2014
5/7/2014quarterly$0.050.12%5/21/20145/23/20146/13/2014
2/5/2014quarterly$0.050.17%2/26/20142/28/20143/21/2014
10/30/2013quarterly$0.050.22%11/18/201311/20/201312/11/2013
7/31/2013quarterly$0.050.22%8/20/20138/22/20139/12/2013
5/2/2013quarterly$0.050.2%5/21/20135/23/20136/13/2013
2/6/2013quarterly$0.050.18%2/26/20132/28/20133/21/2013
(Data available from 1/1/2013 forward)

Insider Trades

Insider Trading and Institutional Ownership History for Allergan PLC. (NYSE AGN)
Insider Ownership Percentage: 0.36%
Institutional Ownership Percentage: 81.21%
Insider Trades by Quarter for Allergan PLC. (NYSE:AGN)
Institutional Ownership by Quarter for Allergan PLC. (NYSE:AGN)
Insider Trades by Quarter for Allergan PLC. (NYSE AGN)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
5/18/2017Nesli BasgozDirectorSell1,889$220.45$416,430.05View SEC Filing  
3/2/2017Paul BisaroDirectorSell70,000$246.68$17,267,600.00View SEC Filing  
12/8/2016Nesli BasgozDirectorSell500$188.72$94,360.00View SEC Filing  
11/21/2016Brent L. SaundersCEOBuy5,250$189.13$992,932.50View SEC Filing  
11/11/2016Maria Teresa HiladoCFOBuy1,422$210.64$299,530.08View SEC Filing  
6/2/2016Maria Teresa HiladoCFOBuy661$241.57$159,677.77View SEC Filing  
5/11/2016Nesli BasgozDirectorSell459$225.10$103,320.90View SEC Filing  
12/7/2015Nesli BasgozDirectorSell2,300$312.96$719,808.00View SEC Filing  
8/24/2015Paul BisaroChairmanBuy1,000$297.42$297,420.00View SEC Filing  
8/21/2015Brent L SaundersCEOBuy1,000$301.94$301,940.00View SEC Filing  
6/9/2015Nesli BasgozDirectorSell2,200$297.89$655,358.00View SEC Filing  
11/26/2014William MeuryInsiderSell4,550$269.14$1,224,587.00View SEC Filing  
9/8/2014Albert Paonessa IIIInsiderSell6,642$230.49$1,530,914.58View SEC Filing  
4/22/2014Scott ShermanEVPSell14,500$155.82$2,259,390.00View SEC Filing  
2/21/2014Louis Lavigne, Jr.DirectorSell5,400$125.79$679,266.00View SEC Filing  
2/19/2014Dawn HudsonDirectorSell4,200$126.35$530,670.00View SEC Filing  
2/19/2014Jeffrey EdwardsCFOSell38,900$126.39$4,916,571.00View SEC Filing  
2/19/2014Raymond DiradoorianEVPSell23,000$126.66$2,913,180.00View SEC Filing  
2/18/2014Scott ShermanEVPSell5,001$125.74$628,825.74View SEC Filing  
1/14/2014Scott WhitcupVPSell42,000$117.80$4,947,600.00View SEC Filing  
12/27/2013Julian GangolliVPSell52,500$110.05$5,777,625.00View SEC Filing  
12/20/2013Scott WhitcupVPSell33,000$108.80$3,590,400.00View SEC Filing  
10/15/2013Trevor JonesDirectorSell2,000$90.14$180,280.00View SEC Filing  
9/16/2013Albert HummelDirectorSell6,200$137.81$854,422.00View SEC Filing  
9/16/2013Trevor JonesDirectorSell2,000$89.78$179,560.00View SEC Filing  
9/4/2013George Fred WilkinsonInsiderSell16,749$138.00$2,311,362.00View SEC Filing  
9/4/2013Jack MichelsonDirectorSell6,064$139.54$846,170.56View SEC Filing  
8/29/2013David BuchenInsiderSell10,000$135.56$1,355,600.00View SEC Filing  
8/26/2013Albert HummelDirectorSell40,000$134.44$5,377,600.00View SEC Filing  
8/20/2013Paul BisaroCEOSell50,000$135.30$6,765,000.00View SEC Filing  
8/15/2013Albert Paonessa IIIInsiderSell5,476$135.89$744,133.64View SEC Filing  
8/15/2013Trevor JonesDirectorSell2,000$89.89$179,780.00View SEC Filing  
8/14/2013R Todd JoyceCFOSell15,000$137.98$2,069,700.00View SEC Filing  
8/13/2013Albert HummelDirectorSell10,000$133.85$1,338,500.00View SEC Filing  
8/12/2013Cathy KlemaDirectorSell1,667$133.03$221,761.01View SEC Filing  
8/12/2013David BuchenInsiderSell17,000$133.03$2,261,510.00View SEC Filing  
8/9/2013Ronald TaylorDirectorSell5,000$135.14$675,700.00View SEC Filing  
8/6/2013Jeffrey EdwardsCFOSell69,200$91.17$6,308,964.00View SEC Filing  
8/5/2013Charles EbertVPSell8,244$136.25$1,123,245.00View SEC Filing  
8/5/2013Michel FeldmanDirectorSell10,000$136.94$1,369,400.00View SEC Filing  
8/2/2013Robert StewartInsiderSell14,564$136.02$1,980,995.28View SEC Filing  
7/15/2013Trevor M JonesDirectorSell2,000$91.15$182,300.00View SEC Filing  
6/17/2013Trevor M JonesDirectorSell2,000$101.25$202,500.00View SEC Filing  
5/15/2013Trevor M JonesDirectorSell2,000$103.40$206,800.00View SEC Filing  
5/9/2013Jeffrey L EdwardsCFOSell84,000$103.49$8,693,160.00View SEC Filing  
3/14/2013Charles M MayrInsiderSell1,000$91.77$91,770.00View SEC Filing  
3/12/2013Michael J FedidaDirectorSell8,000$89.00$712,000.00View SEC Filing  
11/26/2012Trevor M JonesDirectorSell2,500$91.30$228,250.00View SEC Filing  
10/5/2012David E I PyottCEOSell616,300$93.73$57,765,799.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Allergan PLC. (NYSE:AGN)
Latest Headlines for Allergan PLC. (NYSE AGN)
Source:
DateHeadline
Allergan PLC. (AGN) versus NephroGenex (NRXGQ) Critical SurveyAllergan PLC. (AGN) versus NephroGenex (NRXGQ) Critical Survey
www.americanbankingnews.com - November 16 at 5:08 PM
Allergan plc. (AGN) Ex-Dividend Date Scheduled for November 16, 2017 - NasdaqAllergan plc. (AGN) Ex-Dividend Date Scheduled for November 16, 2017 - Nasdaq
www.nasdaq.com - November 16 at 10:53 AM
Generic Drugs Stock Performance Review -- Catalyst Pharma, Flexion Therapeutics, Supernus Pharma and AllerganGeneric Drugs Stock Performance Review -- Catalyst Pharma, Flexion Therapeutics, Supernus Pharma and Allergan
www.bizjournals.com - November 16 at 10:53 AM
An Undervalued, Wide-Moat Name in HealthcareAn Undervalued, Wide-Moat Name in Healthcare
finance.yahoo.com - November 16 at 10:53 AM
Inside Novartis’s Ophthalmology Drugs NowInside Novartis’s Ophthalmology Drugs Now
finance.yahoo.com - November 16 at 10:53 AM
Allergan to Present at the Evercore ISI 2017 Biopharma Catalyst/Deep Dive ConferenceAllergan to Present at the Evercore ISI 2017 Biopharma Catalyst/Deep Dive Conference
finance.yahoo.com - November 16 at 10:53 AM
Allergan (AGN) Announces FDA Approval For Use of VRAYLAR in Maintenance Treatment of SchizophreniaAllergan (AGN) Announces FDA Approval For Use of VRAYLAR in Maintenance Treatment of Schizophrenia
www.streetinsider.com - November 15 at 2:20 AM
Head to Head Contrast: NephroGenex (NRXGQ) versus Allergan plc (AGN)Head to Head Contrast: NephroGenex (NRXGQ) versus Allergan plc (AGN)
www.americanbankingnews.com - November 15 at 1:24 AM
Ex-Dividend Reminder: U.S. Physical Therapy, Allergan and AmgenEx-Dividend Reminder: U.S. Physical Therapy, Allergan and Amgen
www.nasdaq.com - November 14 at 4:07 PM
Allergans Vraylar Gets FDA Nod for Maintenance TherapyAllergan's Vraylar Gets FDA Nod for Maintenance Therapy
www.zacks.com - November 14 at 4:07 PM
Senators Question Allergan Over Its Market Monopoly - Seeking AlphaSenators Question Allergan Over Its 'Market Monopoly' - Seeking Alpha
seekingalpha.com - November 14 at 4:06 PM
Overactive Bladder Causes Significant Burden, Regardless of Age Amongst AdultsOveractive Bladder Causes Significant Burden, Regardless of Age Amongst Adults
finance.yahoo.com - November 14 at 4:06 PM
Here's What's Behind Synergy Pharmaceuticals' 15.6% Drop TodayHere's What's Behind Synergy Pharmaceuticals' 15.6% Drop Today
finance.yahoo.com - November 14 at 4:06 PM
Allergan Receives FDA Approval For Label Expansion Of VRAYLAR - Quick FactsAllergan Receives FDA Approval For Label Expansion Of VRAYLAR - Quick Facts
www.nasdaq.com - November 13 at 6:20 PM
Allergan to sell a quarter of its Teva stake in first quarter of 2018Allergan to sell a quarter of its Teva stake in first quarter of 2018
www.reuters.com - November 13 at 6:20 PM
Allergan Receives FDA Approval For Use of VRAYLAR™ (cariprazine) in the Maintenance Treatment of SchizophreniaAllergan Receives FDA Approval For Use of VRAYLAR™ (cariprazine) in the Maintenance Treatment of Schizophrenia
finance.yahoo.com - November 13 at 8:10 AM
Allergan wins FDA approval for use of Vraylar in maintenance treatment of schizophreniaAllergan wins FDA approval for use of Vraylar in maintenance treatment of schizophrenia
finance.yahoo.com - November 13 at 8:10 AM
Amgen (AMGN), Allergan (AGN) Receive Positive CHMP Opinion For ABP 215 for The Treatment of Certain Types Of CancerAmgen (AMGN), Allergan (AGN) Receive Positive CHMP Opinion For ABP 215 for The Treatment of Certain Types Of Cancer
www.streetinsider.com - November 10 at 7:37 PM
Allergan (AGN) a Sell on Sinking Industry Group RankAllergan (AGN) a Sell on Sinking Industry Group Rank
investorplace.com - November 10 at 3:35 PM
Tevas Stock Could Crash Another 50% After Debt Cut to JunkTeva's Stock Could Crash Another 50% After Debt Cut to Junk
finance.yahoo.com - November 7 at 10:14 PM
Senators question Allergan CEO on tribe patent dealSenators question Allergan CEO on tribe patent deal
www.cnbc.com - November 7 at 3:58 PM
Allergan Keeps Heading Lower. Is It Time to Buy?Allergan Keeps Heading Lower. Is It Time to Buy?
www.fool.com - November 7 at 9:14 AM
$3B lifeline for Teva Pharmaceutical? - Seeking Alpha$3B lifeline for Teva Pharmaceutical? - Seeking Alpha
seekingalpha.com - November 6 at 9:21 PM
Allergans Q3 Proves Growth Is Dead - Seeking AlphaAllergan's Q3 Proves Growth Is Dead - Seeking Alpha
seekingalpha.com - November 6 at 9:21 PM
ETFs with exposure to Allergan Plc : November 6, 2017ETFs with exposure to Allergan Plc : November 6, 2017
finance.yahoo.com - November 6 at 4:19 PM
Teva Survives Price Cut As Billionaire Reportedly Mulls StakeTeva Survives Price Cut As Billionaire Reportedly Mulls Stake
finance.yahoo.com - November 6 at 4:19 PM
Allergan PLC. (AGN) Given Outperform Rating at Credit Suisse GroupAllergan PLC. (AGN) Given Outperform Rating at Credit Suisse Group
www.americanbankingnews.com - November 6 at 11:38 AM
FY2017 EPS Estimates for Allergan PLC. (AGN) Boosted by Cantor FitzgeraldFY2017 EPS Estimates for Allergan PLC. (AGN) Boosted by Cantor Fitzgerald
www.americanbankingnews.com - November 6 at 8:06 AM
FY2017 EPS Estimates for Allergan PLC. Raised by Gabelli (AGN)FY2017 EPS Estimates for Allergan PLC. Raised by Gabelli (AGN)
www.americanbankingnews.com - November 6 at 8:06 AM
FY2017 Earnings Estimate for Allergan PLC. Issued By William Blair (AGN)FY2017 Earnings Estimate for Allergan PLC. Issued By William Blair (AGN)
www.americanbankingnews.com - November 6 at 8:06 AM
Raising the White Flag on Allergan: Best of KassRaising the White Flag on Allergan: Best of Kass
finance.yahoo.com - November 6 at 1:42 AM
Action Alerts PLUS: Bulls Cheer Apple Results, Fed Chairman NomineeAction Alerts PLUS: Bulls Cheer Apple Results, Fed Chairman Nominee
finance.yahoo.com - November 5 at 3:39 PM
Allergan PLC. (AGN) Expected to Announce Quarterly Sales of $4.28 BillionAllergan PLC. (AGN) Expected to Announce Quarterly Sales of $4.28 Billion
www.americanbankingnews.com - November 5 at 4:54 AM
Zacks: Analysts Expect Allergan PLC. (AGN) to Announce $4.76 Earnings Per ShareZacks: Analysts Expect Allergan PLC. (AGN) to Announce $4.76 Earnings Per Share
www.americanbankingnews.com - November 3 at 7:34 PM
Allergan Plc :AGN-US: Earnings Analysis: Q3, 2017 By the Numbers : November 3, 2017Allergan Plc :AGN-US: Earnings Analysis: Q3, 2017 By the Numbers : November 3, 2017
finance.yahoo.com - November 3 at 3:33 PM
Allergans Drop Provides 10 Important Investing LessonsAllergan's Drop Provides 10 Important Investing Lessons
finance.yahoo.com - November 3 at 9:51 AM
Teva Stock Plunges on Earnings Results, but Its Still Not a BuyTeva Stock Plunges on Earnings Results, but It's Still Not a Buy
finance.yahoo.com - November 2 at 8:59 PM
Allergan PLC. (AGN) PT Lowered to $191.00 at Cantor FitzgeraldAllergan PLC. (AGN) PT Lowered to $191.00 at Cantor Fitzgerald
www.americanbankingnews.com - November 2 at 1:16 PM
CEO of Botox maker Allergan on Mohawk tribe patent deal: 'It wasn't desperation, it was tenacity'CEO of Botox maker Allergan on Mohawk tribe patent deal: 'It wasn't desperation, it was tenacity'
finance.yahoo.com - November 2 at 2:07 AM
Allergan Might Stage a Stunning ReversalAllergan Might Stage a Stunning Reversal
finance.yahoo.com - November 1 at 9:05 PM
Edited Transcript of AGN earnings conference call or presentation 1-Nov-17 12:30pm GMTEdited Transcript of AGN earnings conference call or presentation 1-Nov-17 12:30pm GMT
finance.yahoo.com - November 1 at 9:05 PM
CEO of Botox maker Allergan on Mohawk tribe patent deal: ...CEO of Botox maker Allergan on Mohawk tribe patent deal: ...
finance.yahoo.com - November 1 at 9:05 PM
Allergan to begin selling its 10 percent stake in TevaAllergan to begin selling its 10 percent stake in Teva
finance.yahoo.com - November 1 at 9:05 PM
Cramer Remix: Why Wall Street has suddenly turned positive on KelloggCramer Remix: Why Wall Street has suddenly turned positive on Kellogg
finance.yahoo.com - November 1 at 9:05 PM
Allergan CEO: Mohawk tribe patent deal not desperation, i...Allergan CEO: Mohawk tribe patent deal not desperation, i...
finance.yahoo.com - November 1 at 9:05 PM
Cramer Remix: Why Wall Street has suddenly turned positiv...Cramer Remix: Why Wall Street has suddenly turned positiv...
finance.yahoo.com - November 1 at 9:05 PM
CEO of Botox maker Allergan on Mohawk tribe patent deal: It wasnt desperation, it was tenacityCEO of Botox maker Allergan on Mohawk tribe patent deal: 'It wasn't desperation, it was tenacity'
www.cnbc.com - November 1 at 7:45 PM
Allergan shares rise 4% after Q3 profit beatAllergan shares rise 4% after Q3 profit beat
www.marketwatch.com - November 1 at 4:03 PM
Allergan reports 3Q earnings loss on charges, but tops expectationsAllergan reports 3Q earnings loss on charges, but tops expectations
www.usatoday.com - November 1 at 4:03 PM
Noteworthy Wednesday Option Activity: AGN, PBI, DBDNoteworthy Wednesday Option Activity: AGN, PBI, DBD
www.nasdaq.com - November 1 at 4:03 PM

Social Media

Financials

Chart

Allergan PLC. (NYSE AGN) Chart for Friday, November, 17, 2017
Loading chart…

This page was last updated on 11/17/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.